Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma

Abstract

A novel method to simultaneously measure liquid solid mass transfer and external wetting efficiency was employed at column to particle ratios of 10, 6 and 3. Two prewetting procedures representing the upper (Kan) and lower (Levec) hysteresis branches were used. For a multipoint distributor on a Kan prewetted bed wetting efficiency and the specific mass transfer coefficient were almost unaffected by column diameter. The multipoint distributor on a Levec prewetted bed exhibited a decrease in specific mass transfer with decreasing column diameter. Point source experiments resulted in significantly lower wetting and mass transfer measurements with an increasing trend with respect to decreasing column diameter. The results indicate that with proper distribution and prewetting, the effect of column diameter on averaged wetting and liquid–solid mass transfer is almost negligible, a powerful result considering the importance of these parameters on reaction experiments. © 2012 Canadian Society for Chemical Engineering

A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum‐based chemotherapy

“…Using the concurrent cisplatin and irinotecan administration schedule, we showed objective tumor responses in 47% of chemo-naive NSCLC patients with 1-year survival rate of 63.3%. 14 In the current study, 40.6% of patients with previously treated NSCLC responded to the second-line irinotecan and cisplatin therapy, which is quite comparable to our first-line response rate and also the results of other trials wherein the irinotecan and cisplatin regimen was used in a front-line setting (Table 7).…”

“…10 When given together with cisplatin, which has a different toxicity profile, irinotecan showed synergistic antitumor effect in vitro and significant antitumor activity in the firstline setting, as summarized in Table 7. 7,[11][12][13][14] In a second-line setting, however, 2 Japanese studies showed conflicting results on its activity against NSCLC. 15,16 Negoro et al treated 26 previously treated NSCLC patients with 100 mg irinotecan/m 2 every week and observed no response while they reported a 34% response rate in chemotherapy-naive patients in the same study.…”

“…[11][12][13] However, there is a growing body of evidence that suggests that the concurrent same-day administration of cisplatin and irinotecan, as demonstrated in the current study, may better exploit their therapeutic synergy and minimize toxicities. 14,17 The major mechanism of cisplatin resistance is through rapid repair of platinum-DNA adducts. This repair requires unscheduled DNA synthesis, which in turn requires uncoiling of the damaged section of DNA.…”

Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer

“…The eligibility of study subjects were described in detail elsewhere [10], and should have adequate hepatic and renal functions defined as, serum bilirubin level ≤1.5 times, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit (UNL) of the institutional reference range, and serum creatinine ≤1.5 mg/dl. Table 1 shows their characteristics.…”

The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer

“…This study subjects were described in detail elsewhere [12]. Treatment consisted of irinotecan 80 mg/m 2 i.v.…”